<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0163945.ref027">
 <label>27</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ferenci</surname>
   <given-names>P</given-names>
  </name>, 
  <name>
   <surname>Bernstein</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Lalezari</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Cohen</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Luo</surname>
   <given-names>Y</given-names>
  </name>, 
  <name>
   <surname>Cooper</surname>
   <given-names>C</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV</article-title>. 
  <source>N Engl J Med</source>. 
  <year>2014</year>;
  <volume>370</volume>(
  <issue>21</issue>):
  <fpage>1983</fpage>â€“
  <lpage>92</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1402338</pub-id> .
  <?supplied-pmid 24795200?>
  <pub-id pub-id-type="pmid">24795200</pub-id>
 </mixed-citation>
</ref>
